Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Imaging CAR T cell therapy with PSMA-targeted positron emission tomography.

Minn I, Huss DJ, Ahn HH, Chinn TM, Park A, Jones J, Brummet M, Rowe SP, Sysa-Shah P, Du Y, Levitsky HI, Pomper MG.

Sci Adv. 2019 Jul 3;5(7):eaaw5096. doi: 10.1126/sciadv.aaw5096. eCollection 2019 Jul.


In Vivo Imaging With Confirmation by Histopathology for Increased Rigor and Reproducibility in Translational Research: A Review of Examples, Options, and Resources.

Gabrielson K, Maronpot R, Monette S, Mlynarczyk C, Ramot Y, Nyska A, Sysa-Shah P.

ILAR J. 2018 Dec 1;59(1):80-98. doi: 10.1093/ilar/ily010.


Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S.

J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7.


Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.

Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA, Ellis RJ, Richie CT, Harvey BK, Dannals RF, Pomper MG, Bonci A, Michaelides M.

Science. 2017 Aug 4;357(6350):503-507. doi: 10.1126/science.aan2475.


Regulatory Forum Opinion Piece*: Imaging Applications in Toxicologic Pathology-Recommendations for Use in Regulated Nonclinical Toxicity Studies.

Maronpot RR, Nyska A, Troth SP, Gabrielson K, Sysa-Shah P, Kalchenko V, Kuznetsov Y, Harmelin A, Schiffenbauer YS, Bonnel D, Stauber J, Ramot Y.

Toxicol Pathol. 2017 Jun;45(4):444-471. doi: 10.1177/0192623317710014.


An Fc-Small Molecule Conjugate for Targeted Inhibition of the Adenosine 2A Receptor.

Hsiao PY, Kalin JH, Sun IH, Amin MN, Lo YC, Chiang MJ, Giddens J, Sysa-Shah P, Gabrielson K, Wang LX, Powell JD, Cole PA.

Chembiochem. 2016 Oct 17;17(20):1951-1960. doi: 10.1002/cbic.201600337. Epub 2016 Aug 26.


Echocardiographic Characterization of a Murine Model of Hypertrophic Obstructive Cardiomyopathy Induced by Cardiac-specific Overexpression of Epidermal Growth Factor Receptor 2.

Sørensen LL, Bedja D, Sysa-Shah P, Liu H, Maxwell A, Yi X, Pozios I, Olsen NT, Abraham TP, Abraham R, Gabrielson K.

Comp Med. 2016;66(4):268-77.


[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.

Minn I, Koo SM, Lee HS, Brummet M, Rowe SP, Gorin MA, Sysa-Shah P, Lewis WD, Ahn HH, Wang Y, Banerjee SR, Mease RC, Nimmagadda S, Allaf ME, Pomper MG, Yang X.

Oncotarget. 2016 Aug 30;7(35):56471-56479. doi: 10.18632/oncotarget.10602.


A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.

Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, Azad BB, Pomper MG, Nimmagadda S.

Oncotarget. 2016 Mar 1;7(9):10215-27. doi: 10.18632/oncotarget.7143.


Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.

Sysa-Shah P, Tocchetti CG, Gupta M, Rainer PP, Shen X, Kang BH, Belmonte F, Li J, Xu Y, Guo X, Bedja D, Gao WD, Paolocci N, Rath R, Sawyer DB, Naga Prasad SV, Gabrielson K.

Cardiovasc Res. 2016 Mar 1;109(3):358-73. doi: 10.1093/cvr/cvv274. Epub 2015 Dec 21.


Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.

Yang X, Minn I, Rowe SP, Banerjee SR, Gorin MA, Brummet M, Lee HS, Koo SM, Sysa-Shah P, Mease RC, Nimmagadda S, Allaf ME, Pomper MG.

Oncotarget. 2015 Oct 20;6(32):33733-42. doi: 10.18632/oncotarget.5254.


Electrocardiographic Characterization of Cardiac Hypertrophy in Mice that Overexpress the ErbB2 Receptor Tyrosine Kinase.

Sysa-Shah P, Sørensen LL, Abraham MR, Gabrielson KL.

Comp Med. 2015 Aug;65(4):295-307.


ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.

Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, Paolocci N, Aon MA, Nagane M, Kuppusamy P, Steenbergen C, Gabrielson K.

Am J Physiol Heart Circ Physiol. 2015 Oct;309(8):H1271-80. doi: 10.1152/ajpheart.00517.2014. Epub 2015 Aug 7.


Parkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain.

Kageyama Y, Hoshijima M, Seo K, Bedja D, Sysa-Shah P, Andrabi SA, Chen W, Höke A, Dawson VL, Dawson TM, Gabrielson K, Kass DA, Iijima M, Sesaki H.

EMBO J. 2014 Dec 1;33(23):2798-813. doi: 10.15252/embj.201488658. Epub 2014 Oct 27.


Geranylgeranylacetone blocks doxorubicin-induced cardiac toxicity and reduces cancer cell growth and invasion through RHO pathway inhibition.

Sysa-Shah P, Xu Y, Guo X, Pin S, Bedja D, Bartock R, Tsao A, Hsieh A, Wolin MS, Moens A, Raman V, Orita H, Gabrielson KL.

Mol Cancer Ther. 2014 Jul;13(7):1717-28. doi: 10.1158/1535-7163.MCT-13-0965. Epub 2014 Apr 15.


Generation of a cre recombinase-conditional Nos1ap over-expression transgenic mouse.

Auer DR, Sysa-Shah P, Bedja D, Simmers JL, Pak E, Dutra A, Cohn R, Gabrielson KL, Chakravarti A, Kapoor A.

Biotechnol Lett. 2014 Jun;36(6):1179-85. doi: 10.1007/s10529-014-1473-x. Epub 2014 Feb 22.


Loss of NAC1 expression is associated with defective bony patterning in the murine vertebral axis.

Yap KL, Sysa-Shah P, Bolon B, Wu RC, Gao M, Herlinger AL, Wang F, Faiola F, Huso D, Gabrielson K, Wang TL, Wang J, Shih IeM.

PLoS One. 2013 Jul 26;8(7):e69099. doi: 10.1371/journal.pone.0069099. Print 2013.


Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.

Sysa-Shah P, Xu Y, Guo X, Belmonte F, Kang B, Bedja D, Pin S, Tsuchiya N, Gabrielson K.

PLoS One. 2012;7(8):e42805. doi: 10.1371/journal.pone.0042805. Epub 2012 Aug 9.


A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.

Pramanik D, Campbell NR, Das S, Gupta S, Chenna V, Bisht S, Sysa-Shah P, Bedja D, Karikari C, Steenbergen C, Gabrielson KL, Maitra A, Maitra A.

Oncotarget. 2012 Jun;3(6):640-50.

Supplemental Content

Loading ...
Support Center